|
|
|
|
|
|
|
|
|
|
Olaparib
The FDA’s recent approval of olaparib (Lynparza) for women with BRCA-mutated advanced ovarian cancer marks a significant therapeutic advance for women with the malignancy, but the specific indication is far too restrictive and the drug should be offered to many more patients, according to Maurie Markman, MD.
In fact, Markman said, clinical trial evidence indicates that some women with high-grade serous ovarian cancer who do not test positive for a BRCA mutation also may respond to olaparib, and they should have an opportunity to decide in consultation with their physicians whether the drug is appropriate for them......
The FDA’s recent approval of olaparib (Lynparza) for women with BRCA-mutated
advanced ovarian cancer marks a significant therapeutic advance for
women with the malignancy, but the specific indication is far too
restrictive and the drug should be offered to many more patients,
according to Maurie Markman, MD.
In fact, Markman said, clinical trial evidence indicates that some women with high-grade serous ovarian cancer who do not test positive for a BRCA mutation also may respond to olaparib, and they should have an opportunity to decide in consultation with their physicians whether the drug is appropriate for them. - See more at: http://www.onclive.com/web-exclusives/Expert-Says-More-Women-Should-Qualify-for-Olaparib-Than-Label-Allows#sthash.wy7W6grb.dpuf
In fact, Markman said, clinical trial evidence indicates that some women with high-grade serous ovarian cancer who do not test positive for a BRCA mutation also may respond to olaparib, and they should have an opportunity to decide in consultation with their physicians whether the drug is appropriate for them. - See more at: http://www.onclive.com/web-exclusives/Expert-Says-More-Women-Should-Qualify-for-Olaparib-Than-Label-Allows#sthash.wy7W6grb.dpuf
The FDA’s recent approval of olaparib (Lynparza) for women with BRCA-mutated
advanced ovarian cancer marks a significant therapeutic advance for
women with the malignancy, but the specific indication is far too
restrictive and the drug should be offered to many more patients,
according to Maurie Markman, MD.
In fact, Markman said, clinical trial evidence indicates that some women with high-grade serous ovarian cancer who do not test positive for a BRCA mutation also may respond to olaparib, and they should have an opportunity to decide in consultation with their physicians whether the drug is appropriate for them. - See more at: http://www.onclive.com/web-exclusives/Expert-Says-More-Women-Should-Qualify-for-Olaparib-Than-Label-Allows#sthash.wy7W6grb.dpuf
In fact, Markman said, clinical trial evidence indicates that some women with high-grade serous ovarian cancer who do not test positive for a BRCA mutation also may respond to olaparib, and they should have an opportunity to decide in consultation with their physicians whether the drug is appropriate for them. - See more at: http://www.onclive.com/web-exclusives/Expert-Says-More-Women-Should-Qualify-for-Olaparib-Than-Label-Allows#sthash.wy7W6grb.dpuf
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.